Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

Dementia and geriatric cognitive disorders - 1 Jan 2005

Visser Pieter Jelle, Scheltens Philip, Pelgrim Esther, Verhey Frans R J

Abstract excerpt

BACKGROUND: Only a subgroup of subjects with probable AD shows cognitive improvement after treatment with cholinesterase inhibitors. OBJECTIVES: To investigate whether atrophy of the medial temporal lobe and the apolipoprotein E (APOE) genotype could predict cognitive improvement in subjects with probable AD treated with rivastigmine. METHODS: 121 subjects with mild to moderate probable AD were treated for 26...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atrophy
Share to Cholinesterase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Genetics

Share to Mental Status Schedule

Share to Neuroprotective Agents

Share to Psychometrics

Share to Temporal Lobe

Source

Identifiers

PMID: 15627759
DOI: 10.1159/000082883

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.PMID 15627759Read ↗

Metrifonate treatment of AD: influence of APOE genotype.Semantic proximity Read ↗

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.Semantic proximity Read ↗

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Semantic proximity Read ↗

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Semantic proximity Read ↗

Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.Semantic proximity Read ↗

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.Semantic proximity Read ↗

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.Semantic proximity Read ↗

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.Semantic proximity Read ↗

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.Semantic proximity Read ↗

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?Semantic proximity Read ↗

Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.Semantic proximity Read ↗

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.